These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35220997)

  • 21. Farnesoid X receptor modulators 2014-present: a patent review.
    Sepe V; Distrutti E; Fiorucci S; Zampella A
    Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Sanyal AJ
    Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling.
    Gu M; Zhang S; Zhao Y; Huang J; Wang Y; Li Y; Fan S; Yang L; Ji G; Tong Q; Huang C
    Pharmacol Res; 2017 Jul; 121():22-32. PubMed ID: 28428116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease.
    McGettigan BM; McMahan RH; Luo Y; Wang XX; Orlicky DJ; Porsche C; Levi M; Rosen HR
    J Biol Chem; 2016 Oct; 291(44):23058-23067. PubMed ID: 27605663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
    Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
    Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
    Shah RA; Alkhouri N; Kowdley KV
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):251-260. PubMed ID: 32686578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
    Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
    Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FXR: structures, biology, and drug development for NASH and fibrosis diseases.
    Tian SY; Chen SM; Pan CX; Li Y
    Acta Pharmacol Sin; 2022 May; 43(5):1120-1132. PubMed ID: 35217809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
    Zhou W; Anakk S
    Mol Cell Endocrinol; 2022 Jun; 549():111616. PubMed ID: 35304191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism.
    Kumari A; Pal Pathak D; Asthana S
    Int J Biol Sci; 2020; 16(13):2308-2322. PubMed ID: 32760200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
    Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H
    Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Farnesoid X receptor activation induces the degradation of hepatotoxic 1-deoxysphingolipids in non-alcoholic fatty liver disease.
    Gai Z; Gui T; Alecu I; Lone MA; Hornemann T; Chen Q; Visentin M; Hiller C; Hausler S; Kullak-Ublick GA
    Liver Int; 2020 Apr; 40(4):844-859. PubMed ID: 31883408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
    Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
    Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment.
    Zhu L; Baker RD; Zhu R; Baker SS
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.